FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
FibroGen (NASDAQ: FGEN) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference, scheduled for April 7-10, 2025. The company's management team will be conducting one-on-one meetings with investors on Wednesday, April 9th, 2025. Interested investors are advised to reach out to their Needham representatives to schedule meetings.
FibroGen (NASDAQ: FGEN) ha annunciato la sua partecipazione alla prossima 24ª Conferenza Virtuale Annuale di Needham sulla Salute, programmata per il 7-10 aprile 2025. Il team di gestione dell'azienda condurrà incontri individuali con gli investitori il mercoledì 9 aprile 2025. Gli investitori interessati sono invitati a contattare i loro rappresentanti di Needham per programmare gli incontri.
FibroGen (NASDAQ: FGEN) ha anunciado su participación en la próxima 24ª Conferencia Virtual Anual de Salud de Needham, programada para el 7-10 de abril de 2025. El equipo de gestión de la empresa llevará a cabo reuniones individuales con inversores el miércoles 9 de abril de 2025. Se aconseja a los inversores interesados que se pongan en contacto con sus representantes de Needham para programar reuniones.
FibroGen (NASDAQ: FGEN)은 2025년 4월 7일부터 10일까지 예정된 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 2025년 4월 9일 수요일에 투자자와의 일대일 회의를 진행할 예정입니다. 관심 있는 투자자는 회의를 예약하기 위해 니드햄 대표에게 연락할 것을 권장합니다.
FibroGen (NASDAQ: FGEN) a annoncé sa participation à la prochaine 24e Conférence Virtuelle Annuelle de Santé de Needham, prévue du 7 au 10 avril 2025. L'équipe de direction de l'entreprise organisera des réunions individuelles avec des investisseurs le mercredi 9 avril 2025. Les investisseurs intéressés sont invités à contacter leurs représentants de Needham pour planifier des réunions.
FibroGen (NASDAQ: FGEN) hat seine Teilnahme an der bevorstehenden 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt, die vom 7. bis 10. April 2025 stattfinden wird. Das Management-Team des Unternehmens wird am Mittwoch, den 9. April 2025 Einzelgespräche mit Investoren führen. Interessierte Investoren werden gebeten, sich an ihre Needham-Vertreter zu wenden, um Meetings zu vereinbaren.
- None.
- None.
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.
FibroGen’s management team will be available for one-on-one meetings on Wednesday, April 9th. Interested investors should contact their representative at Needham.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
FAQ
When is FibroGen (FGEN) participating in the Needham Healthcare Conference 2025?
How can investors meet with FGEN management at the Needham Healthcare Conference?
What type of meetings will FGEN hold at the 2025 Needham Healthcare Conference?
Is the 2025 Needham Healthcare Conference where FGEN is participating virtual or in-person?
